Glenmark Pharma on Tuesday said the United States’ health regulator USFDA has cleared its investigational new drug application to initiate phase one study of GBR 1342, a humanised monoclonal antibody for treatment of multiple myeloma. The news helped Glenmark stock to rise 2% to Rs 729.90 in early trade. This is Glenmark’s second investigational new drug from its immuno-oncology portfolio to enter clinical trials. The first-in-human phase 1 study of GBR 1342 will enrol subjects with multiple myeloma who have exhausted available therapies. “... our flagship biotechnology platform and antibody science are beginning to become a reality for patients now that we have a second oncology candidate entering clinical trials,” Glenmark Pharma President and Chief Scientific Officer Kurt Stoeckli said.

Source: Hindustan Times May 16, 2017 07:18 UTC